These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 10468696)

  • 81. Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: clinical characteristics, outcomes, and incidences.
    Chang L; Tong K; Ameen V
    Am J Gastroenterol; 2010 Apr; 105(4):866-75. PubMed ID: 20197759
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Update on the Management of Diarrhea-Predominant Irritable Bowel Syndrome: Focus on Rifaximin and Eluxadoline.
    Rivkin A; Rybalov S
    Pharmacotherapy; 2016 Mar; 36(3):300-16. PubMed ID: 26971716
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Double-blind study of the effect of cisapride on constipation and abdominal discomfort as components of the irritable bowel syndrome.
    Schütze K; Brandstätter G; Dragosics B; Judmaier G; Hentschel E
    Aliment Pharmacol Ther; 1997 Apr; 11(2):387-94. PubMed ID: 9146780
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Naloxone treatment for irritable bowel syndrome--a randomized controlled trial with an oral formulation.
    Hawkes ND; Rhodes J; Evans BK; Rhodes P; Hawthorne AB; Thomas GA
    Aliment Pharmacol Ther; 2002 Sep; 16(9):1649-54. PubMed ID: 12197844
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Alverine citrate fails to relieve the symptoms of irritable bowel syndrome: results of a double-blind, randomized, placebo-controlled trial.
    Mitchell SA; Mee AS; Smith GD; Palmer KR; Chapman RW
    Aliment Pharmacol Ther; 2002 Jun; 16(6):1187-95. PubMed ID: 12030962
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Randomized clinical trial: macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome.
    Chapman RW; Stanghellini V; Geraint M; Halphen M
    Am J Gastroenterol; 2013 Sep; 108(9):1508-15. PubMed ID: 23835436
    [TBL] [Abstract][Full Text] [Related]  

  • 87. The clinical potential of ramosetron in the treatment of irritable bowel syndrome with diarrhea (IBS-D).
    Min YW; Rhee PL
    Therap Adv Gastroenterol; 2015 May; 8(3):136-42. PubMed ID: 25949526
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Nucleotide supplementation: a randomised double-blind placebo controlled trial of IntestAidIB in people with Irritable Bowel Syndrome [ISRCTN67764449].
    Dancey CP; Attree EA; Brown KF
    Nutr J; 2006 Jun; 5():16. PubMed ID: 16762076
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Review article: evaluation of drugs in experimental gut distension models.
    Pappas TN; Mangel AW; Lawson C
    Aliment Pharmacol Ther; 1999 May; 13 Suppl 2():54-6. PubMed ID: 10429741
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation.
    Evans BW; Clark WK; Moore DJ; Whorwell PJ
    Cochrane Database Syst Rev; 2007 Oct; (4):CD003960. PubMed ID: 17943807
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Alosetron approved for treatment of irritable bowel syndrome.
    Miller JL
    Am J Health Syst Pharm; 2000 Mar; 57(6):519. PubMed ID: 10754758
    [No Abstract]   [Full Text] [Related]  

  • 92. Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis.
    Ford AC; Brandt LJ; Young C; Chey WD; Foxx-Orenstein AE; Moayyedi P
    Am J Gastroenterol; 2009 Jul; 104(7):1831-43; quiz 1844. PubMed ID: 19471254
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Alosetron in irritable bowel syndrome: strategies for its use in a common gastrointestinal disorder.
    Lembo A; Weber HC; Farraye FA
    Drugs; 2003; 63(18):1895-905. PubMed ID: 12930162
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Platelet serotonin transporter in patients with diarrhea-predominant irritable bowel syndrome both before and after treatment with alosetron.
    Bellini M; Rappelli L; Blandizzi C; Costa F; Stasi C; Colucci R; Giannaccini G; Marazziti D; Betti L; Baroni S; Mumolo MG; Marchi S; Del Tacca M
    Am J Gastroenterol; 2003 Dec; 98(12):2705-11. PubMed ID: 14687821
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Tenapanor Treatment of Patients With Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized, Placebo-Controlled Efficacy and Safety Trial.
    Chey WD; Lembo AJ; Rosenbaum DP
    Am J Gastroenterol; 2017 May; 112(5):763-774. PubMed ID: 28244495
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Linaclotide in irritable bowel syndrome with constipation: A Phase 3 randomized trial in China and other regions.
    Yang Y; Fang J; Guo X; Dai N; Shen X; Yang Y; Sun J; Bhandari BR; Reasner DS; Cronin JA; Currie MG; Johnston JM; Zeng P; Montreewasuwat N; Chen GZ; Lim S
    J Gastroenterol Hepatol; 2018 May; 33(5):980-989. PubMed ID: 29319191
    [TBL] [Abstract][Full Text] [Related]  

  • 97. "Prokinetic" treatment of constipation-predominant irritable bowel syndrome: a placebo-controlled study of cisapride.
    Van Outryve M; Milo R; Toussaint J; Van Eeghem P
    J Clin Gastroenterol; 1991 Feb; 13(1):49-57. PubMed ID: 2007745
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Optimizing outcomes with alosetron hydrochloride in severe diarrhea-predominant irritable bowel syndrome.
    Lucak SL
    Therap Adv Gastroenterol; 2010 May; 3(3):165-72. PubMed ID: 21180598
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Randomized, double-blind, placebo-controlled trial of prednisolone in post-infectious irritable bowel syndrome.
    Dunlop SP; Jenkins D; Neal KR; Naesdal J; Borgaonker M; Collins SM; Spiller RC
    Aliment Pharmacol Ther; 2003 Jul; 18(1):77-84. PubMed ID: 12848628
    [TBL] [Abstract][Full Text] [Related]  

  • 100. A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome.
    Matsueda K; Harasawa S; Hongo M; Hiwatashi N; Sasaki D
    Digestion; 2008; 77(3-4):225-35. PubMed ID: 18667823
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.